BPC-157 Complete Drug-Drug Interaction Profile: What Women Need to Know

What Is BPC-157 and How Does It Work?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a naturally occurring protein fragment isolated from human gastric juice. No FDA-approved drug product exists. In the United States, it is available only through 503A compounding pharmacies, meaning each batch is prepared for an individual patient under a prescription and is not subject to the same pre-market approval process as licensed drugs.

The peptide has been studied almost exclusively in rodent and canine models. Sikiric et al., writing in the Journal of Physiology and Pharmacology in 2018, summarized two decades of animal data showing effects on tendon, ligament, gut mucosa, bone, and central nervous system tissues. That paper remains the most-cited mechanistic reference, but it describes animal work. No phase II or phase III randomized controlled trial in humans has been published as of January 2025.

The Core Molecular Mechanisms

Understanding where BPC-157 acts in the body is the only way to reason about its drug-drug interactions, because no formal human interaction studies exist.

Nitric oxide (NO) pathway modulation. Animal data show that BPC-157 stabilizes the NO system, blunting NO overproduction in inflammatory states while preserving baseline vasodilation. Sikiric et al. (2016) in Current Pharmaceutical Design described this as a central mechanism linking the peptide's gut-protective and vascular effects. This means any drug that itself alters NO, including nitrates, PDE-5 inhibitors, or L-arginine supplements, could have additive or opposing vascular effects when combined with BPC-157.

Dopamine and serotonin system engagement. Rodent studies demonstrate that BPC-157 rescues dopamine system function after neurotoxic insults and counteracts serotonin syndrome features in some animal models. A 2016 paper by Sikiric's group in Current Neuropharmacology showed BPC-157 attenuated haloperidol-induced catalepsy and reversed some SSRI-related behavioral changes in rats. The pharmacological implication is a plausible interaction with SSRIs, SNRIs, antipsychotics, and any drug that touches monoamine metabolism.

Growth hormone receptor sensitization. BPC-157 appears to upregulate growth hormone receptor expression in tendon fibroblasts and liver tissue in rodent models, as described by Sikiric et al. In Gut (1994), one of the earliest mechanistic papers. This is directly relevant for women using GH secretagogues (like sermorelin or ipamorelin), peptide stacks marketed for body composition, or IGF-1-modulating therapies.

Angiogenesis and VEGF upregulation. BPC-157 consistently increases vascular endothelial growth factor (VEGF) expression in wound-healing models. Any drug that inhibits angiogenesis, such as bevacizumab or other anti-VEGF agents, may theoretically oppose this effect.

Why Mechanism-Based Reasoning Is the Only Tool Available

There are no pharmacokinetic studies in humans reporting BPC-157 half-life, volume of distribution, protein binding, or cytochrome P450 involvement. The absence of CYP data means you cannot predict metabolic drug-drug interactions the way you can with a licensed drug. The interactions discussed throughout this article are mechanism-inferred, not directly measured in clinical trials. This is an important evidence gap, and women deserve to know it plainly.

The Complete Drug-Drug Interaction Profile: Class by Class

Because BPC-157 touches multiple receptor systems simultaneously, its interaction risks span several drug classes that are commonly prescribed to women.

NSAIDs and COX Inhibitors

BPC-157 was originally characterized as a gut-protective agent. Animal data show it prevents and reverses gastric ulceration caused by aspirin, indomethacin, and other NSAIDs by preserving mucosal blood flow and upregulating cytoprotective prostaglandins. A 2003 rodent study by Sikiric et al. In European Journal of Pharmacology demonstrated that BPC-157 co-administration reduced NSAID-induced intestinal perforation rates significantly in rats.

The interaction is potentially favorable from a GI-protection standpoint but creates two problems. First, the combination might mask GI side effects that would otherwise prompt a woman to stop an NSAID before serious mucosal damage occurs. Second, women with endometriosis or dysmenorrhea who rely on high-dose NSAIDs and add BPC-157 are combining two agents that both affect prostaglandin biology with no human data to define the combined effect.

Opioids

In rodent models, BPC-157 modulates opioid receptor sensitivity. Sikiric et al. (1999) in Biomedicine and Pharmacotherapy reported that BPC-157 attenuated morphine-induced hyperalgesia and withdrawal behaviors in rats, suggesting an interaction at the mu-opioid receptor level or downstream signaling. For a woman managing chronic pain who is on buprenorphine, tramadol, or opioid analgesics, adding BPC-157 may alter analgesic response in unpredictable ways. The magnitude of this effect in humans is unknown.

SSRIs, SNRIs, and Other Antidepressants

This is one of the most clinically relevant interaction categories for women, who are prescribed SSRIs at roughly twice the rate of men. A 2016 rodent pharmacology study found BPC-157 counteracted fluoxetine-induced serotonergic excess in animals, suggesting it may blunt the therapeutic effect of SSRIs or alter the risk profile of serotonin-related side effects.

If BPC-157 genuinely modulates serotonin tone downward, women using SSRIs or SNRIs for depression, anxiety, perimenopausal mood symptoms, hot flash management, or premenstrual dysphoric disorder (PMDD) could see reduced drug efficacy. The concern is real enough to warrant a direct conversation with your prescriber before combining these agents.

Antihypertensives and Nitric Oxide Donors

The NO-modulating mechanism makes BPC-157 a potential interactor with:

• ACE inhibitors and ARBs (which increase NO bioavailability)
• Nitrate patches or sublingual nitrates
• Minoxidil (used for female pattern hair loss)
• Hydralazine
• PDE-5 inhibitors (used off-label in women for sexual dysfunction or pulmonary hypertension)

Animal data suggest BPC-157 has a blood pressure-stabilizing effect through NO, but the direction of interaction with antihypertensive drugs depends on baseline vascular tone, dose, and the specific drug. Additive hypotension is a plausible risk, particularly in postmenopausal women whose vasomotor regulation is already altered by estrogen loss.

GH Secretagogues and Peptide Stacks

The peptide market frequently promotes "stacks" combining BPC-157 with sermorelin, ipamorelin, CJC-1295, or tesamorelin. Because BPC-157 may sensitize GH receptors, stacking it with a GH secretagogue could amplify IGF-1 exposure beyond what either agent produces alone. Women with a personal or family history of hormone-sensitive cancers, including breast cancer, should be especially cautious. The American Society of Clinical Oncology's position on IGF-1 and breast cancer risk noted the biologic plausibility of IGF-1 promoting breast epithelial proliferation, though causation remains debated. No study has tested a BPC-157/GH secretagogue combination in humans.

Corticosteroids

BPC-157 and corticosteroids have opposing effects on tissue healing. Corticosteroids suppress fibroblast proliferation and collagen synthesis; BPC-157 appears to stimulate both. In a rat model reported by Sikiric et al. (2010) in Journal of Orthopaedic Research, BPC-157 partially reversed corticosteroid-impaired tendon healing. Women receiving corticosteroids for autoimmune disease, asthma, or inflammatory conditions who add BPC-157 may see attenuated steroid effects on tissue suppression, but the clinical net result in humans is entirely uncharacterized.

Anticoagulants and Antiplatelet Agents

BPC-157 affects vessel wall biology through NO and VEGF pathways. Animal data suggest it promotes angiogenesis and vessel stabilization. The interaction with warfarin, apixaban, rivaroxaban, or clopidogrel has not been studied, but any agent that alters vascular biology warrants caution in women taking anticoagulants for atrial fibrillation, DVT prophylaxis, or antiphospholipid syndrome, a condition affecting women disproportionately.

Proton Pump Inhibitors and H2 Blockers

Both BPC-157 and acid-suppressive drugs act on gastric mucosal protection, but through different pathways. BPC-157 preserves mucosal blood flow and prostaglandin synthesis; PPIs block the proton pump. The combination is unlikely to produce a dangerous pharmacodynamic interaction, but it is redundant in most scenarios, and adding an unregulated peptide to manage GI symptoms that a PPI is already treating is not a risk-benefit calculation supported by human evidence.

Sex-Specific Physiology: How Hormonal Status Changes the Risk Picture

No published study has examined BPC-157 pharmacokinetics or pharmacodynamics specifically in women. The following framework synthesizes what is known about sex differences in the underlying pathways BPC-157 engages, and what that means across life stages.

Reproductive Years (Ages 18-40)

Estrogen and progesterone fluctuate substantially across the menstrual cycle and influence both NO bioavailability and serotonin receptor density. Because BPC-157 touches both pathways, its effects may not be constant across the cycle. Women in the luteal phase (higher progesterone) have altered vascular reactivity compared to the follicular phase, meaning a drug that modulates NO tone could behave differently depending on where you are in your cycle. No data confirm this, but it is a biologically plausible source of variability.

Women with PCOS have chronically elevated androgens, altered insulin sensitivity, and frequently use metformin, combined oral contraceptives, or spironolactone. BPC-157's GH-sensitizing properties could theoretically interact with the already-dysregulated IGF-1 axis in PCOS. Women with endometriosis who use continuous progestin suppression or GnRH agonists are altering their hormonal milieu in ways that have not been mapped against BPC-157 pharmacology.

Perimenopause (Typically Ages 45-55)

Perimenopausal estrogen fluctuation destabilizes vascular tone, serotonin signaling, and bone remodeling, three of the exact pathways BPC-157 is purported to affect. Women in perimenopause are also more likely to be prescribed SSRIs for mood symptoms, antihypertensives for newly emerging cardiovascular risk, and low-dose hormonal therapies. Each of these prescriptions is a potential interaction point. The risk of additive hypotension from combining an antihypertensive with BPC-157's NO-modulating properties deserves specific attention in this age group.

Postmenopause

Postmenopausal women using systemic hormone therapy (estradiol with or without progesterone) have a different baseline NO bioavailability than untreated postmenopausal women, because estrogen upregulates endothelial NO synthase. The net vascular effect of adding BPC-157 to that background is unknown. Women with osteoporosis who are on bisphosphonates, denosumab, or romosozumab are adding a bone-active biologic, and BPC-157's purported effects on bone healing (demonstrated in rat fracture models by Novinscak et al. In Journal of Orthopaedic Research, 2008) have not been studied alongside approved osteoporosis agents.

Pregnancy, Lactation, and Contraception

BPC-157 is contraindicated in pregnancy. No human safety data exist. No animal teratogenicity or embryotoxicity studies have been published in peer-reviewed journals as of January 2025. The absence of data is not reassurance. The FDA has not assigned a pregnancy category to BPC-157 because it is not an approved drug. Under the current FDA Pregnancy and Lactation Labeling Rule (PLLR), compounded agents without an NDA have no labeling, meaning your prescriber is operating without any regulatory guidance on fetal risk.

BPC-157's VEGF-upregulating effects are particularly concerning in the context of pregnancy. VEGF is critical to placental vascularization, and dysregulation of VEGF signaling is associated with preeclampsia and fetal growth restriction. A 2004 review in the New England Journal of Medicine established that placental VEGF imbalance is mechanistically linked to preeclampsia. An exogenous peptide that amplifies VEGF signaling in a dose-uncharacterized way should not be used during pregnancy.

Lactation. Transfer of BPC-157 to breast milk is unknown. The peptide is a 15-amino-acid chain with a molecular weight of approximately 1.4 kDa. Small peptides can transfer into breast milk, and gastric acid may not fully degrade them in a nursing infant. Because the risk cannot be quantified and the benefit to the nursing mother has not been established in any human trial, use during breastfeeding should be avoided.

Contraception. Women of reproductive age who use BPC-157 should use reliable contraception throughout the course. If pregnancy is suspected or confirmed, BPC-157 should be stopped immediately and the prescribing clinician notified.

Trying to conceive. Women trying to conceive should not use BPC-157. The VEGF and GH-sensitizing mechanisms are active during implantation and early placentation, periods that are particularly sensitive to exogenous signaling molecules.

Who This May Be Appropriate For (and Who Should Avoid It)

This is not a drug with a clean approved-use profile. The following is framed by life stage and condition, based on the current state of preclinical evidence and known risk factors.

Women Who Face the Highest Risk From BPC-157

• Pregnant women or those trying to conceive: absolute contraindication
• Breastfeeding women: avoid; transfer and infant safety unknown
• Women on SSRIs, SNRIs, or antidepressants for PMDD, perimenopause, or depression: serotonin pathway interaction plausible
• Women with hormone-sensitive cancers (current or history): IGF-1 and VEGF amplification are biological concerns
• Women on anticoagulation for antiphospholipid syndrome, DVT, or cardiac indications: uncharacterized vascular biology interaction
• Women with PCOS and elevated IGF-1: GH receptor sensitization may worsen already-elevated IGF-1

Women Where Evidence Is Thinnest

All of them. There are no female-specific human trials. Women have been historically underrepresented in peptide and sports-medicine research, and BPC-157 is no exception. A 2021 analysis in the Journal of Clinical Investigation confirmed that preclinical research consistently underrepresents female animal subjects, making extrapolation from rodent BPC-157 studies to women doubly uncertain. Sex differences in pain processing, connective tissue biology, and GI physiology are well-documented, yet no BPC-157 study has stratified by sex.

Women Where the Risk-Benefit Calculation Is Least Unfavorable

• Women with documented chronic tendinopathy or ligament injury who have exhausted approved treatments, are not pregnant or breastfeeding, and are not on any of the drug classes listed above
• Postmenopausal women not on systemic hormone therapy who have simple musculoskeletal recovery goals and no active medication interactions

Even in these cases, the evidence base is animal data only. Any use should be under direct clinician supervision with a clear stop date and monitoring plan.

Monitoring if You and Your Clinician Decide to Proceed

If BPC-157 is prescribed by a clinician who has reviewed your full medication list and life stage, reasonable monitoring includes:

• Blood pressure checks at baseline and at 2 weeks, given NO-modulating effects
• Mood symptom tracking on a validated scale (PHQ-9 or similar) if you are on an SSRI or SNRI
• IGF-1 serum level at baseline and after the first cycle if you are also on a GH secretagogue
• Menstrual cycle diary for women in reproductive years, to capture any cycle changes that could signal hormonal disruption
• Immediate stop and clinical review if any new bleeding, severe headache, visual changes, or swelling develops

The standard compounded dose range is 250 to 500 mcg subcutaneously once or twice daily for 4 to 8 week cycles, as commonly prescribed off-label based on the Sikiric rodent dosing literature. These doses have not been validated in any human pharmacokinetic study, and the therapeutic window in humans is unknown.

The Evidence Gap: What Research in Women Is Still Missing

Women deserve direct acknowledgment of how little is known specifically about them and BPC-157.

No published study has examined:

• BPC-157 pharmacokinetics in women at any life stage
• BPC-157 effects on menstrual cycle regularity or hormonal axes
• BPC-157 drug interactions in women taking combined oral contraceptives, hormone therapy, or PCOS medications
• BPC-157 safety in perimenopause or postmenopause
• Any BPC-157 outcome in a female human subject, published in a peer-reviewed journal

The NIH mandate requiring sex as a biological variable in preclinical research, effective 2016, should have begun improving this. Most BPC-157 animal studies published before 2016 used male rodents exclusively. More recent papers from Sikiric's group have begun including female animals in some models, but sex-stratified analyses remain rare in the published literature.

The Menopause Society's 2023 position statement on compounded hormone therapy does not address peptides directly, but its caution about compounded agents lacking safety and efficacy data applies with equal force to BPC-157: "The Menopause Society does not support the use of compounded hormone therapy unless conventional hormone therapy products are not available."